Tactogen is a biopharma startup developing empathogen medicines using machine learning and targeted assays to identify novel small molecules that improve mental health outcomes. The company focuses on creating safer and more effective treatments for anxiety, depression, and stress-related disorders, aiming to enhance accessibility to mental wellness solutions.
Funding
$7.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for mental health disorders like anxiety, depression, and stress-related disorders often have limited efficacy or undesirable side effects. Existing psychedelic therapies require intensive clinical monitoring, limiting accessibility and increasing costs for patients.
Solution
Tactogen is developing a new generation of empathogen medicines designed to improve mental wellness outcomes with enhanced safety and accessibility. The company employs machine learning and targeted assays to identify novel small molecules with therapeutic potential. These molecules are designed to facilitate psychotherapy, decision-making, and psychological growth with reduced need for clinical monitoring compared to existing psychedelic treatments. Tactogen's approach focuses on creating take-home prescription empathogens that are both effective and convenient for patients.
Target Audience
The primary target audience includes individuals suffering from anxiety, depression, and stress-related disorders, as well as mental health professionals seeking safer and more accessible treatment options.
Features
- Utilizes machine learning for rapid drug discovery and identification of promising molecules.
- Focuses on developing novel MDMA derivatives with improved safety profiles.
- Aims to create pharmaceutical preparations suitable for take-home prescriptions.
- Developing intellectual property around drug discovery methods and novel molecules.